Table 3

One-way sensitivity analysis of cost and effectiveness of current strategy (of single HIV test) and proposed strategy (of addition of second HIV test during pregnancy)

HIV incidence (probability)StrategyCost (C)Effect (E)C/E (USD per QALY gained)Incremental cost-effectiveness ratio
0.0001Proposed$6.6765.000.10 265Cost saving
Current$55.8339.091.42 824
0.005Proposed$7.2964.930.11 226Cost saving
Current$55.8339.091.42 824
0.010Proposed$7.9164.870.12 188Cost saving
Current$55.8339.091.42 824
0.015Proposed$8.5264.800.13 152Cost saving
Current$55.8339.091.42 824
0.020Proposed$9.1464.740.14 118Cost saving
Current$55.8339.091.42 824
0.025Proposed$9.7664.680.15 086Cost saving
Current$55.8339.091.42 824
0.030Proposed$10.3764.610.16 056Cost saving
Current$55.8339.091.42 824
0.035Proposed$10.9964.550.17 027Cost saving
Current$55.8339.091.42 824
0.040Proposed$11.6164.480.18 001Cost saving
Current$55.8339.091.42 824
0.045Proposed$12.2264.420.18 977Cost saving
Current$55.8339.091.42 824
0.05Proposed$12.8464.350.19 955Cost saving
Current$55.8339.091.42 824
  • C/E, cost-effectiveness ratio; QALY, quality-adjusted life years.